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Hemoglobin cycling in hemodialysis patients treated with
recombinant human erythropoietin.
Background. Treatment with recombinant human erythro-
poietin (rHuEPO) has been a major advance for the manage-
ment of anemia in patients on hemodialysis. Therapy, however,
is often observed to be associated with recurrent cyclic fluctu-
ations in hemoglobin levels. The purpose of this analysis was
to describe the phenomenology of hemoglobin cycling during
rHuEPO treatment.
Methods. Data were analyzed for 281 hemodialysis patients
treated at Winthrop-University Hospital Dialysis Centers be-
tween 1998 and 2003. Eligible patients’ first full 1-year period
with less than 10 hospital days was studied. Hemoglobin cycling
(cycles with amplitude >1.5 g/dL and duration >8 weeks) and
excursions (half of one full cycle) were analyzed.
Results. Greater than 90% of patients experienced
hemoglobin cycling. The mean number of hemoglobin excur-
sions was 3.1 ± 1.1 per patient/year. The mean amplitude per
hemoglobin excursion was 2.51 ± 0.89 g/dL. The mean dura-
tion of hemoglobin excursions was 10.3 ± 5.1 weeks. Factors
associated with initiation of up excursions included increases
in rHuEPO dose (84%), intravenous iron treatment initiation
or increase in dose (27%), posthospital discharge (36%), fac-
tors associated with down excursions included rHuEPO dose
hold (15%) or dose reduction (62%), infection (6%), discon-
tinuation of intravenous iron therapy (5%), and hospitalization
(14%). Patients with frequent hemoglobin cycling (>two full
cycles per year) were characterized as being more responsive
to rHuEPO [index of EPO responsiveness (ERI) 1036 ± 659
compared to 1992 ± 701 for other patients] (P = 0.02).
Conclusion. Hemoglobin cycling is a common occurrence in
rHuEPO-treated hemodialysis patients. It is most closely as-
sociated with frequent rHuEPO dose changes, hospitalization,
and iron treatment practices.
Anemia is one of the important complications of end-
stage renal disease (ESRD) [1], and treatment with re-
combinant human erythropoietin (rHuEPO) has been
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a great advance in the management of this problem
[2, 3]. Treatment to achieve partial correction of pa-
tients’ hemoglobin level results in improved quality of
life [4] and is associated with reduced risk for mortal-
ity [5] and hospitalization [6]. However, therapy with
rHuEPO is quite different than biologic erythropoietic
processes; treatment involves short, intermittent, non-
physiologic bursts of plasma EPO availability which
do not directly coincide either temporally or in mag-
nitude with physiologic perturbations. It may not be
surprising, therefore, that it is routinely observed that
during treatment with rHuEPO in hemodialysis pa-
tients that the level of hemoglobin fluctuates greatly.
More specifically, hemoglobin levels tend to rise and
fall in a cyclic pattern, one that varies from patient to
patient.
The phenomenon of hemoglobin cycling has not been
widely studied, but may have an adverse impact on
patient outcomes since wide movement of hemoglobin
values is not a part of normal homeostasis. Indeed,
under normal conditions, the body’s oxygen sensing,
EPO-producing, and erythropoietic systems are closely
regulated and coordinated [7] to maintain hemoglobin
levels and oxygen delivery within a narrow range. In
contrast, with hemoglobin cycling, fluctuation in oxygen
delivery to vital organs occurs. Repeated episodes of rel-
ative ischemia and the resultant tissue compensation in
organs such as the heart may result in disordered growth
signals, pathologic organ function, and suboptimal pa-
tient outcomes. Hemoglobin cycling may also complicate
clinical management of hemodialysis patients as nephrol-
ogists and anemia nurse managers respond to changes
in hemoglobin levels with changes in rHuEPO dosing,
which may lead to more dramatic or frequent hemoglobin
cycling. The purpose of this study was to describe the phe-
nomenology of hemoglobin cycling in rHuEPO-treated
hemodialysis patients, to analyze etiologic factors, to as-
sess the impact of hemoglobin fluctuations on iron stor-
age, and to study factors associated with a subpopula-
tion of patients that demonstrated a greater degree of
cycling.
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METHODS
Subjects
All patients on chronic maintenance outpatient hemo-
dialysis at Winthrop-University Hospital’s Mineola
Center between 1998 and 2003 were screened for eligi-
bility. This time period was selected because there were
no significant changes during this time in either the unit’s
anemia or iron treatment protocols. In addition, there
were no significant changes to Medicare reimbursement
policy for rHuEPO after amendment of the prior Pro-
gram Memoranda AB-98-10 (published March 1998),
changing aspects of the Hematocrit Measurement Audit
policy.
A dataset of patients was created to allow analysis of
the phenomenon of hemoglobin cycling. Patients were
excluded from analysis if they survived on dialysis for
less than 1 year. The first 1 year period after January 1,
1998 in which the patient had less than 10 hospital days
was chosen as that patient’s analysis year. Only 1 year was
analyzed per patient. Subjects with no years with less than
10 hospital days were excluded from analysis because of
the powerful effect of intercurrent illness on hemoglobin
stability. Other reasons for exclusion included any of the
following factors being present during the analysis year:
no treatment with rHuEPO, transfusion of red blood cells,
medication treatment as part of participation in a clini-
cal research study, or history of gastrointestinal or other
major bleeding within 6 months.
During the period of study, a protocol for rHuEPO
dose adjustment was used by the hemodialysis center.
Hemoglobin levels were measured every 2 weeks for
all patients, including study patients. Based on the re-
sults, the protocol directed rHuEPO dose adjustments.
When the hemoglobin rose above 13.5 g/dL, the dose of
rHuEPO was held for 2 weeks. The dose would be re-
sumed, reduced by 25% to 50% when hemoglobin de-
creased <13.0 g/dL. For hemoglobin values >12.5 g/dL,
the rHuEPO dose would be reduced by 25%. No change
in dose was directed for hemoglobin between 11.0
and 12.5 g/dL. When hemoglobin was <11.0 g/dL, the
rHuEPO dose would be increased 25% to 50%. The
protocol dose adjustments were made by an anemia
nurse manager. For any decrease in hemoglobin of more
than 1 g/dL in a 2-week period, the physician was con-
tacted to evaluate for possible bleeding or hemolysis. All
rHuEPO treatment was by intravenous administration
at each hemodialysis treatment. Iron management was
guided by individual physician judgment. Approximately
65% of patients were treated with intravenous iron, as
short-term repletive courses (52% of patients) and/or as
maintenance therapy (28% of patients), noting that these
numbers are >100% since some patients received both
repletive courses and maintenance therapy at different
times during the study year.
Definitions
A hemoglobin cycle was defined as a series of measured
hemoglobin levels in an individual patient that oscillated
over time, in which the levels decreased or increased over
time, and then reversed direction and approximately re-
traced the initial trajectory. The precise starting and end-
ing hemoglobin levels might differ, the rate of change
in the up and down swing might differ, but an approx-
imate cycle would be completed. The hemoglobin cycle
midpoint was defined as the hemoglobin level halfway
between the high and low end of a complete cycle. Half
of one hemoglobin cycle defined a hemoglobin excur-
sion. The duration of a hemoglobin excursion was de-
fined as the number of weeks from the high and low
hemoglobin measures in the excursion. Only excursions
of 4 or more weeks’ duration were analyzed. The am-
plitude of a hemoglobin excursion was the absolute dif-
ference between hemoglobin level at the start and end
of the excursion. Hemoglobin excursions with amplitude
less than 1.5 g/dL were not considered to be clinically sig-
nificant. Therefore, only hemoglobin excursions with am-
plitude greater than 1.5 g/dL were included in the analysis.
The velocity of a hemoglobin excursion is the amplitude
divided by the duration and expressed in g/dL/week).
For a patient with hemoglobin of 13.2 g/dL, whose level
decreases over 10 weeks to 10.7 g/dL, the hemoglobin
excursion amplitude is 2.5 g/dL and the velocity is 0.25
g/dL/week.
Statistical analysis
Data were collected using electronic forms created in a
database software program (Microsoft Access 2003) and
transferred to a spreadsheet program (Microsoft Excel
2003). Statistical analyses were performed using Graph-
pad statistical software (San Diego, CA, USA) and SPSS
package release version 10.1.0 (SPSS Inc., Chicago, IL,
USA). Descriptive statistics are presented as mean with
standard deviations or with 95% confidence intervals.
Differences between continuous variables were com-
pared using Student unpaired t test. A P value of less than
0.05 was considered to represent statistical significance.
Responsiveness to rHuEPO treatment was assessed by
creation of an index of EPO responsiveness (ERI), cal-
culated as the weekly rHuEPO dose (units/week) divided
by the hemoglobin concentration. The lower the result,
the more sensitive is the response to rHuEPO, conversely
a high ERI indicates relative resistance to rHuEPO
erythropoietic effects. We used logistic regression to
identify factors significantly associated with hemoglobin
cycling. Nonsignificant covariates were removed by back-
ward selection. A panel of demographic (age, gender, dia-
betes, dialysis vintage, cause of ESRD, and ethnicity/race)
and clinical factors (comorbidity, hospitalizations, medi-
cations, Kt/V, urea reduction ratio, laboratory results, and
Fishbane and Berns: Hemoglobin cycling in patients treated with rHuEPO 1339
Table 1. Patient characteristics
Total study population number 281
Mean age years 61.4 ± 13.5
Gender (male:female)% 53:47
Diabetes mellitus% 39.5
Dialysis vintage m 29.3 ± 28.4
Ethnicity and race%
Caucasian 63.1
African American 19.5
Hispanic 10.5
Asian 4.4
Other 2.5
Cause of end-stage renal disease %
Diabetes mellitus 35.4
Hypertension 30.3
Chronic glomerulonephritis 14.2
Polycystic kidney disease 6.3
Other 13.8
interdialytic weight gain) were analyzed as possible uni-
variate predictors of hemoglobin cycling.
Because of the profound effect of intercurrent illness
on hemoglobin levels, a secondary analysis was conducted
in which all perihospitalization periods were excluded.
Specifically, hemoglobin levels during the 4 weeks before
and 4 weeks after a hospitalization were removed from
this secondary analysis.
RESULTS
The characteristics of the study population of 281 pa-
tients are displayed in Table 1. During the period re-
viewed, the mean hemoglobin level was 11.8 g/dL (95%
CI 11.2-12.1 g/dL). The mean number of rHuEPO dose
changes per year per patient was 6.3 ± 3.3, and the
distribution of dose changes per patient is displayed in
Figure 1.
Greater than 90% of patients experienced hemoglobin
cycling as defined as one or more annual, full, extended
cycle of amplitude >1.5 hemoglobin g/dL of a duration
greater than 8 weeks. A graphic example of hemoglobin
cycling in an individual patient is displayed in Figure
2. The mean number of hemoglobin excursions (half
of one cycle) per patient per year was 3.1 ± 1.1 (dis-
tribution displayed in Fig. 3). The mean amplitude per
hemoglobin excursion was 2.51 ± 0.89 g/dL. The distribu-
tion of hemoglobin excursion amplitudes is displayed in
Figure 4. At the peak of excursions, the mean hemoglobin
was 12.8 ± 1.8 g/dL, at the nadir the mean hemoglobin
was 10.3 g/dL. The mean duration of a hemoglobin ex-
cursion was 10.3 ± 5.1 weeks. For up excursions (ris-
ing hemoglobin) the mean amplitude was significantly
greater, 2.7 ± 0.9 g/dL, than for down excursions, 2.4 ± 0.8
g/dL (P = 0.04). The mean duration of up excursions was
not significantly different from the duration of down ex-
cursions (10.2 ± 5.8 weeks compared to 10.5 ± 4.0 weeks
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Fig. 1. Distribution of the number of recombinant human erythropoi-
etin (rHuEPO) dose changes per patient in 1 year.
respectively) (P = NS). The mean velocity of hemoglobin
excursions was 0.24 g/dL/week hemoglobin change.
The relationship between a variety of demographic
and clinical factors and hemoglobin cycling was stud-
ied. Clinical factors associated with initiation of up ex-
cursions included increases in rHuEPO dose (84% of
cases), intravenous iron treatment initiation or increase
in dose (27%), and hospital discharge within the prior
30 days (36%). Factors associated with down excursions
included rHuEPO dose hold (15%), rHuEPO dose re-
duction (62%), infection (6%), discontinuation of intra-
venous iron therapy (5%), and hospitalization (14%). By
multivariate analysis, changes in rHuEPO dose, changes
or initiation of intravenous iron and recent hospitaliza-
tion were all independent predictors of hemoglobin cy-
cling (P < 0.05). Changes in rHuEPO dose leading to a
hemoglobin cycle occurred with hemoglobin outside the
target 11 to 12 g/dL range in 80.1% of cases. Hemoglobin
cycling was not significantly affected by stable weekly
maintenance intravenous iron dosing. Clinical factors not
associated with cycling included other laboratory results,
Kt/V or urea reduction ratio, mean intradialytic weight
gain, other medications, comorbidity, or demographic
factors. The effect of hospitalizations on hemoglobin tra-
jectory was often to reset or initiate a hemoglobin cycle.
Patients had a mean of 1.1 ± 1.2 hospital admissions in
the year of study. With 40.4% of admissions, there was
a shift in hemoglobin trajectory in the 4 weeks prior to
admission, with a mean decrease of 2.8 ± 2.2 g/dL. Within
4 weeks after hospital discharge, 35% of patients entered
upwards hemoglobin excursions with mean amplitude of
3.5±2.4 g/dL. After discharge, the mean weekly rHuEPO
dose in the 4 weeks after hospitalization was 75.5 ± 52.2%
higher than in the 4 weeks prior to admission. When the
perihospitalization period was excluded from analysis,
the impact of rHuEPO dose changes and iron treatment
as primary causes of hemoglobin cycles was amplified. Ei-
ther rHuEPO dose changes or iron treatment initiation
or dose increases were associated with nearly 100% of
these hemoglobin excursions.
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Fig. 2. A graphic example of hemoglobin
(Hgb) cycling in a 59-year-old diabetic man,
showing both hemoglobin and recombinant
human erythropoietin (rHuEPO) dose.
0
5
10
15
20
25
30
35
40
N
um
be
r o
f e
xc
u
rs
io
ns
/y
e
a
r,
 
%
0 1 2 3 4 5
Frequency
Fig. 3. Distribution of the number of hemoglobin excursions per
patient in 1 year.
The impact of hemoglobin cycling on iron indices was
analyzed. From the study population, 62 patients who
were not on intravenous iron and who had iron indices
measured in temporal association with peak and nadir
hemoglobin levels during a hemoglobin excursion were
studied. During up hemoglobin excursions, serum ferritin
decreased by a mean of 82.2 ± 56.1 ng/mL per gram in-
crease in hemoglobin (comparing initial and final serum
ferritin) (P < 0.0001). During down hemoglobin excur-
sions, serum ferritin increased by a mean of 51.7 ± 53.9
ng/mL per gram decrease in hemoglobin (P = 0.001).
Transferrin saturation values had great variation in mea-
sured results unrelated to hemoglobin excursions; there
were no statistically significant changes from beginning
to end of hemoglobin excursions.
A subpopulation of patients was identified, character-
ized by more frequent hemoglobin cycling (>two full
cycles per year). These frequent cyclers accounted for
30.1% of the entire population studied. We explored clin-
ical factors that would explain a propensity for more
frequent cycling. The mean amplitude of hemoglobin ex-
cursions was not significantly different between frequent
cyclers and others (2.6 ± 0.9 g/dL compared to 2.6 ± 1.0
g/dL, respectively) (P = NS). The mean duration of a
hemoglobin excursion was significantly shorter for fre-
quent cyclers than others (9.3 ± 4.0 weeks compared
to 11.1 ± 5.5 weeks, respectively) (P = 0.007). To eval-
uate rHuEPO responsiveness between the two groups,
we calculated the ERI: weekly rHuEPO dose (U/week)
divided by hemoglobin. Held rHuEPO doses were not
included in the calculation. Patients who were frequent
cyclers were significantly more responsive to rHuEPO
than others, ERI 1036 ± 659 U/week/g hemoglobin com-
pared to 1992 ± 701 U/week/g hemoglobin, respectively)
(P = 0.02). No other clinical factors were predictive of
frequent cycling behavior.
DISCUSSION
Nephrologists have often observed during rHuEPO
treatment in hemodialysis patients that hemoglobin lev-
els continually rise and fall in undulations or cycles.
Despite this observation, there has been little system-
atic study of the phenomenon. The scientific literature
contains reports of a similar and related phenomenon,
population-based variability of hemoglobin results in
rHuEPO-treated patients. Recently, we reported on
an analysis of 987 hemodialysis patients treated at 11
American hemodialysis units. We found that hemoglobin
variability was widespread, and is a clear characteristic
of rHuEPO-treated hemodialysis patients [7]. In a sim-
ilar study, Lacson, Ofsthun, and Lazarus [8] found that
29% of hemodialysis patients had hemoglobin levels that
moved at least once to above or below a hemoglobin
target range of 11 to 12 g/dL in 1 year of observa-
tion. The purpose of our current study was to analyze
more precisely at the individual patient level, the move-
ment of hemoglobin levels over time. We sought to
describe hemoglobin cycling quantitatively, and to exam-
ine factors that explain the phenomenon. We have found
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The amplitude is the difference between
hemoglobin level at the beginning and end of
an excursion.
that hemoglobin cycling, repeated up and down undula-
tions of hemoglobin levels, is a common phenomenon
in hemodialysis patients treated with rHuEPO. Pa-
tients’ hemoglobin levels follow somewhat predictable,
repeated up and down cycles, interrupted at times by in-
tercurrent illnesses and hospitalizations.
The cause of hemoglobin cycling appears to be mul-
tifactorial. We found changes in rHuEPO dose to be
the most important driver, associated with hemoglobin
excursions in approximately 80% of cases. The dose
of rHuEPO was changed an average of 6.1 times per
patient per year in this study. Our rHuEPO dose ad-
justment protocol, like that used in most dialysis cen-
ters, drives dose changes when the hemoglobin level is
outside of the target range [9]. The National Kidney
Foundation Anemia Treatment Guidelines recommend
a narrow target hemoglobin range of 11 to 12 g/dL [10].
As a result, rHuEPO dose changes, including holding of
doses, are frequently required. The impact of these dose
changes would ideally be a “soft landing” with the re-
sulting hemoglobin remaining in the target range, but
probably much more frequently a new trajectory of
hemoglobin movement is initiated, and not infrequently
hemoglobin levels outside the desired range result. As
the hemoglobin level begins to move and traverses across
the target range, most protocols would not require an-
other dose change. Instead, the next dose adjustment
would generally be made when the hemoglobin is out
of range again, now on the opposite side of the target
range. Then the entire process is repeated, in the reverse
direction. In many patients the result is repeated back
and forth cycling of hemoglobin levels. Furthermore, our
dialysis unit, like most, has a rHuEPO dose protocol that
is essentially “one size fits all.” It is well known, how-
ever, that patient responsiveness to rHuEPO is highly
variable; some patients respond with great sensitivity,
others may be highly resistant [11]. We found that pa-
tients who are more responsive to rHuEPO tend to have
a greater degree of hemoglobin cycling. This finding may
resonate with clinicians who have observed that some pa-
tients respond to rHuEPO dose increases with rapid rises
in hemoglobin resulting in a need to temporarily hold
doses. By the time hemoglobin result is checked again,
the level may have decreased precipitously. Because of
the high degree of variability in rHuEPO response, it
may be unreasonable to expect the “one size fits all” dose
adjustment protocol to maintain hemoglobin levels with
the degree of stability attained in normal homeostasis.
This may be particularly true with the use of pharmaco-
logic rHuEPO treatment; short-acting drugs, intermittent
dosing with brief “bursts” of EPO in plasma [12]. Taken
together, we propose that hemoglobin cycling is primar-
ily a result of several anemia treatment practices, includ-
ing (1) a narrow target hemoglobin range; (2) rHuEPO
dose adjustments; (3) patient variability in rHuEPO re-
sponse, with inflexible dose adjustment protocols that do
not account for patient-specific responsiveness; (4) use of
pharmacologic, intermittent, intravenously administered
EPO replacement using a preparation with a short half-
life; and perhaps (5) the use of single hemoglobin lev-
els obtained on a relatively frequent basis (i.e., every 2
weeks) to prompt rHuEPO dose adjustments.
Hospitalizations have a major impact on anemia man-
agement [13]. Indeed, we found that hospital admissions
often initiated a hemoglobin cycle or reset an existing
cycle. The effect of intercurrent illness such as vascular
access infection on erythropoiesis is often a temporary
relative resistance to rHuEPO treatment [14]. As a re-
sult, the hemoglobin level may decrease and the rHuEPO
dose is increased in response. The blunted erythropoi-
etic response is probably a result of cytokine induction
[15]. Other factors related to hospitalization-associated
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hemoglobin cycling might include missed rHuEPO doses,
changes in rHuEPO dose, surgical or other invasive pro-
cedures with blood loss, and phlebotomy for laboratory
tests. We found that after hospitalization that many pa-
tients had a substantial upward trajectory of hemoglobin.
As patients recover from the intercurrent illness, EPO
responsiveness improves and does so while patients are
often on much higher doses of rHuEPO [13].
Iron status was also found to affect hemoglobin cy-
cling. Intravenous iron therapy was associated with 27%
of rising hemoglobin excursions. This was an expected
finding, very consistent with literature indicating the ro-
bust efficacy of iron therapy in hemodialysis patients [16].
After a course of intravenous iron is completed, there
continues to be fluxes in iron status that may last several
months. The immediate impact of treatment is a reple-
tion of iron stores, reflected best by an increase in serum
ferritin [17]. However, as the hemoglobin level rises in
response, iron is transferred from storage tissues to the
erythron (developing and mature red blood cells) and the
patient continues to have ongoing losses of blood and iron
related to the hemodialysis procedure [18]. As a result,
after the initial increase in serum ferritin with intravenous
iron treatment, both of these factors cause serum ferritin
levels to decrease sharply, often returning back down to
baseline [17]. In this study we found that for each g/dL
increase in hemoglobin during an up hemoglobin excur-
sion, that serum ferritin decreased by 82.2 ± 56.1 mg/dL.
This relationship between iron and erythropoiesis is com-
plicated further by the fact that as the hemoglobin level
rises, the rHuEPO dose will often be decreased. So after
the healthy initial effect of intravenous iron, with a robust
increase in hemoglobin level, 1 to 3 months later the pa-
tient may again experience iron deficiency, but now while
on a reduced dose of rHuEPO. A downward hemoglobin
excursion will often result, explaining our observation of
a complex relationship between intravenous iron dosing
and hemoglobin cycling. In a sense, hemoglobin and iron
cycling are two interwoven processes.
The impact of hemoglobin cycling on patients’ health
outcomes is not known. Under normal conditions of
homeostasis, stable oxygen delivery to tissues is main-
tained by keeping the serum hemoglobin concentra-
tion fairly constant. Reduced oxygen delivery is sensed
primarily through hypoxia-inducible factor-1 present in
the kidney and other tissues [19]. When stimulated,
this system leads to increased renal EPO production
[20]. The bone marrow responds with increased produc-
tion and survival of erythrocyte precursors which enter
the circulation as reticulocytes [21]. This system main-
tains the hemoglobin concentration in response to chal-
lenges such as traumatic blood loss, menstruation, and
hypoxia due to increased altitude. The frequent cycling
of hemoglobin concentrations in hemodialysis patients
treated with rHuEPO is an artificial phenomenon in the
sense that it is not seen in normal healthy homeosta-
sis. Hemoglobin fluctuations of this type may potentially
cause pathologic tissue changes for a variety of reasons.
In the heart, reduced hemoglobin concentration leads to
left ventricular dilatation and hypertrophy [22]. This re-
sults at least in part from changes in intracardiac cellular
growth signaling [23], although the mechanisms are in-
completely understood. As hemoglobin levels rise and
fall in hemodialysis patients, the disordered activation
and resetting of cardiac growth signals could result in
pathologic alterations in cardiac structure and function.
Other tissues and organs throughout the body may also
be sensitive to injury related to variability in hemoglobin
level and oxygen delivery.
In addition to the potential organ damage induced
by the heart’s attempts to compensate for cycling
hemoglobin levels, there may be pathology caused by
wide fluxes of serum EPO levels resulting from repeated
adjustments to rHuEPO doses due to cycling hemoglobin
levels. While our best understanding of the effect of
rHuEPO is its effect on bone marrow in the treatment
of anemia, in recent years it has become clear that many
tissues of the body have functioning cellular EPO recep-
tors [24]. Cells in the brain [25], retina [26], heart [27],
and kidneys [28] all are affected by EPO, receptor bind-
ing results in a cascade of signal transduction and gene
activation. As a result, nonhomeostatic fluxes in serum
EPO levels could potentially impact on the structure and
function of each of these tissues.
Based on the findings from this study, potential strate-
gies for the prevention of hemoglobin cycling emerge.
A wider target hemoglobin range then the current 11 to
12 g/dL would reduce the need for frequent rHuEPO
dose changes. Ideally, clinical performance measures and
reimbursement policy should support such an approach
by avoiding financial or other penalties for occasional
hemoglobin results above or below the target range. It
may be that less frequent measurement of hemoglobin
level and the resulting rHuEPO dose adjustments would
reduce the degree if cycling. Because of the contribution
to hemoglobin cycling of intermittent intravenous iron
treatment strategies, weekly maintenance intravenous
iron dosing should be considered in appropriate pa-
tients to try to achieve “smoother” iron storage kinet-
ics. In addition, research should be encouraged into EPO
replacement strategies that more closely mimic native
EPO physiology. Further research aimed at determining
whether hemoglobin cycling occurs in other rHuEPO-
treated populations such as patients with chronic kidney
disease would be desirable.
CONCLUSION
We have found hemoglobin cycling to be a frequent
finding in hemodialysis patients treated with rHuEPO.
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The most important cause was frequent changes in
rHuEPO dose, probably due in large part to the narrow
hemoglobin target range. In addition, we found that pa-
tients with greater rHuEPO responsiveness tend to have
a greater degree of hemoglobin cycling. Finally, there was
a complex interaction between hemoglobin cycling and
iron storage. Taken together these findings suggest that
the current therapeutic paradigm of hemoglobin moni-
toring, iron treatment, and rHuEPO treatment results in
recurrent nonphysiologic cycling of hemoglobin levels in
hemodialysis patients.
Reprint requests to Steven Fishbane, M.D., 200 Old Country Road,
Suite 135, Mineola, NY 11501.
E-mail:sfishbane@metrorenal.com
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